Goldman Sachs analyst Keyur Parekh reinstated coverage of Sanofi with a Buy rating and EUR 134 price target. The company’s pipeline story remains early and a bit of a "show me" story, the base business execution over the last few years "cannot be faulted," Parekh tells investors in a research note. The analyst says Dupixent continues to deliver meaningful growth and upside relative to consensus expectations. Parekh continues to see Sanofi delivering "superior execution both on the top line and the bottom line."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
- Sanofi receives positive CHMP opinion for Dupixent in eosinophilic esophagitis
- Regeneron, Sanofi: EMA’s CHMP recommends approval of Dupixent in EU
- Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential
- Regeneron, Sanofi announce EC expansion for Dupixent marketing authorization
- Kymera Soars on Promising Results in Skin Disorders
